Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
-
Autolus Therapeutics Announces Changes to its Board of Directors
-
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
-
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
-
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
-
Autolus Therapeutics announces participation in upcoming conferences
-
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
-
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
-
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
-
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023